Phase II trial of paclitaxel in patients with soft-tissue sarcoma

Cancer Investigation

Volumn 16, Issue 7, 1998, Pages 442-446

  Casper, Ephraim S ^a   Waltzman, Roger J ^a   Schwartz, Gary K ^a   Sugarman, Alison ^a   Pfister, David ^a   Ilson, David ^a   Woodruff, James ^a   Leung, Denis ^a   Bertino, Joseph R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CIMETIDINE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EDATREXATE; IFOSFAMIDE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANGIOSARCOMA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCALP; SOFT TISSUE SARCOMA; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031709550     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809011697     Document Type: Article

References (14)

1. Antman KH, Ryan L, Elias A, et al: Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7:126, 1989.
2. Edmonson JH, Ryan, LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11:1269-1275, 1993.
3. Borden EC, Amato, DA, Rosenbaum C, et al: Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5:840-850, 1987.
4. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1778-1781, 1991.
5. Seidman AD, Hochhauser D, Yao TJ, et al: 96 hour paclitaxel after prior short taxane infusion: phase II pharmacokinetic (PK) and pharmacodynamic (PD) study in metastatic breast cancer. Proc Am Soc Clin Oncol 14:113, 1995.
6. McGuire WP, Rowinsky EK, Rosenheim MB, et al: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989.
7. Murphy WK, Fosella FV, Winn RJ, et al: Phase II study of taxol in untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85:384-388, 1993.
8. Ajani JA, Ilson DH, Daugherty K, et al: Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol 22(Suppl 6):35-40, 1995.
9. Li WW, Cordon-Cardo C, Chen Q, et al: Establishment, characterization and drug sensitivity of four new human soft tissue sarcoma cell lines. Int J Cancer 68:514, 1996.
10. Adult Intergroup Soft-Tissue Sarcoma Committee: Recommendations for clinical protocol development and definition of therapeutic response for soft tissue sarcoma. Cancer 46:796-800, 1980.
11. Balcerzak SP, Benedetti J, Weiss GR, Natale RB: A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. Cancer 76:2248-2252, 1995.
12. Gian V, Lynch J, McCarley D, Johnson T: Taxol in the treatment of recurrent or metastatic soft tissue or osteosarcomas. Proc Am Soc Clin Oncol 14:516, 1995.
13. Patel SR, Papadopoulos NE, Plager, C, et al: Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Cancer 78:741-744, 1996.
14. Van Hoesl QGCM, Verweij J, Catimal G, et al: Phase II study with Docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 5:539-542, 1994.